篇名

美國FDA之新冠肺炎新疫苗研發指引──兼論臺灣新冠肺炎疫苗【本期企劃】   試閱

並列篇名

US FDA Guidance on the Development of COVID-19 Vaccine and Some Issues Regarding Domestic Vaccine Development

作者
中文摘要

美國食品藥物管理署於2020年6月發布新冠肺炎新疫苗之研發與發證指引,詳述法規單位的觀點,是研發疫苗的重要參考資料。目前國際上有八支候選疫苗已經或即將進入第三期臨床試驗,其試驗規劃基本上均符合指引的考量。本文將簡介指引中的特殊考量,並據以探討臺灣新冠肺炎疫苗研發的若干問題。

英文摘要

US Food and Drug Administration issued Guidance for Industry titled Development and Licensure of Vaccines to Prevent COVID-19 in June 2020. The guidance describes the Agency’s thinking and is the most importance reference regarding anti-COVID-19 vaccines development. There are 8 candidate vaccines have moved or moving into phase III clinical trial. Study designs of all of the trials are comparable with the considerations in guidance. This article is to introduce the special considerations in the guidance, and then to address some issues regarding domestic anti- COVID-19 vaccines development.

起訖頁

007-022

出版單位
DOI

10.3966/241553062020110049001  複製DOI  DOI查詢

QRCode

數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP